

Supplemental Online Content

Ko D, Lin KJ, Bessette LG, et al. Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020. *JAMA Netw Open*. 2022;5(11):e2242964. doi:10.1001/jamanetworkopen.2022.42964

eTable 1. 12-Month Initiation of Oral Anticoagulant in Oral Anticoagulant-Eligible Incident Atrial Fibrillation Cohort, 2010-2020

eTable 2. OAC Mean Proportion of Days Covered and Nonadherence (Proportion of Days Covered < 80%) in OAC-Initiator Incident Atrial Fibrillation Cohort, 2010-2020

eFigure. OAC Initiation and DOAC Uptake by Race and Additional Clinical Subgroups Over 2010-2020

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. 12-Month Initiation of Oral Anticoagulant in Oral Anticoagulant-Eligible Incident Atrial Fibrillation Cohort, 2010-2020

Characteristics	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
All, N	26782	28275	28136	28544	28755	33443	37659	46018	51236	51037	21603
Dabigatran, n (%)	291 (1.1)	1701 (6.0)	1222 (4.3)	674 (2.4)	349 (1.2)	281 (0.8)	429 (1.1)	313 (0.7)	251 (0.5)	116 (0.2)	15 (0.1)
Rivaroxaban, n (%)	0 (0.0)	118 (0.4)	1066 (3.8)	1932 (6.8)	2300 (8.0)	2176 (6.5)	2377 (6.3)	3367 (7.3)	3111 (6.1)	2648 (5.2)	1135 (5.3)
Apixaban, n (%)	0 (0.0)	0 (0.0)	29 (0.1)	575 (2.0)	1682 (5.8)	3409 (10.2)	4924 (13.1)	7670 (16.7)	10263 (20.0)	11955 (23.4)	5528 (25.6)
Warfarin, n (%)	5114 (19.1)	4463 (15.8)	4402 (15.6)	3577 (12.5)	3104 (10.8)	2984 (8.9)	2579 (6.8)	2432 (5.3)	1449 (2.8)	1098 (2.2)	436 (2.0)
None, %	21377 (79.8)	21993 (77.8)	21417 (76.1)	21786 (76.3)	21320 (74.1)	24594 (73.5)	27350 (72.6)	32237 (70.1)	36164 (70.6)	35221 (69.0)	14492 (67.1)
Age 65-79 years, N	17551	17087	15713	15808	16260	19138	21809	27799	30530	31131	13346
Dabigatran, n (%)	221 (1.3)	1218 (7.1)	806 (5.1)	451 (2.9)	247 (1.5)	203 (1.1)	303 (1.4)	234 (0.8)	180 (0.6)	86 (0.3)	11 (0.1)
Rivaroxaban, n (%)	0 (0.0)	83 (0.5)	711 (4.5)	1249 (7.9)	1510 (9.3)	1438 (7.5)	1624 (7.4)	2381 (8.6)	2196 (7.2)	1863 (6.0)	777 (5.8)
Apixaban, n (%)	0 (0.0)	0 (0.0)	18 (0.1)	364 (2.3)	1008 (6.2)	2026 (10.6)	3042 (13.9)	4815 (17.3)	6542 (21.4)	7777 (25.0)	3533 (26.5)
Warfarin, n (%)	3729 (21.2)	2929 (17.1)	2605 (16.6)	2051 (13.0)	1848 (11.4)	1864 (9.7)	1600 (7.3)	1525 (5.5)	989 (3.2)	750 (2.4)	293 (2.2)
None, n (%)	13601 (77.5)	12857 (75.2)	11573 (73.7)	11693 (74.0)	11647 (71.6)	13608 (71.1)	15240 (69.9)	18845 (67.8)	20624 (67.6)	20656 (66.4)	8733 (65.4)
Age ≥80 years, N	9231	11188	12423	12736	12495	14305	15850	18219	20706	19906	8257
Dabigatran, n (%)	70 (0.8)	483 (4.3)	416 (3.3)	223 (1.8)	102 (0.8)	78 (0.5)	126 (0.8)	79 (0.4)	71 (0.3)	30 (0.2)	4 (0.0)
Rivaroxaban, n (%)	0 (0.0)	35 (0.3)	355 (2.9)	683 (5.4)	790 (6.3)	738 (5.2)	753 (4.7)	986 (5.4)	915 (4.4)	785 (3.9)	358 (4.3)
Apixaban, n (%)	0 (0.0)	0 (0.0)	11 (0.1)	211 (1.7)	674 (5.4)	1383 (9.7)	1882 (11.9)	2855 (15.7)	3721 (18.0)	4178 (21.0)	1995 (24.2)
Warfarin, n (%)	1385 (15.0)	1534 (13.7)	1797 (14.5)	1526 (12.0)	1256 (10.1)	1120 (7.8)	979 (6.2)	907 (5.0)	460 (2.2)	348 (1.7)	143 (1.7)
None, n (%)	7776 (84.2)	9136 (81.7)	9844 (79.2)	10093 (79.2)	9673 (77.4)	10986 (76.8)	12110 (76.4)	13392 (73.5)	15540 (75.1)	14565 (73.2)	5759 (69.7)
Women, N	13871	14572	14324	14574	14438	17011	18876	22901	25837	25725	10770
Dabigatran, n (%)	131 (0.9)	812 (5.6)	571 (4.0)	338 (2.3)	165 (1.1)	127 (0.7)	202 (1.1)	142 (0.6)	111 (0.4)	49 (0.2)	7 (0.1)
Rivaroxaban, n (%)	0 (0.0)	52 (0.4)	526 (3.7)	922 (6.3)	1149 (8.0)	1106 (6.5)	1113 (5.9)	1597 (7.0)	1469 (5.7)	1218 (4.7)	516 (4.8)
Apixaban, n (%)	0 (0.0)	0 (0.0)	14 (0.1)	267 (1.8)	848 (5.9)	1803 (10.6)	2601 (13.8)	4006 (17.5)	5401 (20.9)	6308 (24.5)	2836 (26.3)
Warfarin, n (%)	2505 (18.1)	2294 (15.7)	2234 (15.6)	1795 (12.3)	1555 (10.8)	1464 (8.6)	1300 (6.9)	1189 (5.2)	667 (2.6)	490 (1.9)	204 (1.9)
None, n (%)	11235 (81.0)	11414 (78.3)	10979 (76.6)	11252 (77.2)	10721 (74.3)	12511 (73.5)	13660 (72.4)	15968 (69.7)	18190 (70.4)	17660 (68.6)	7210 (66.9)
Men, N	12911	13703	13812	13970	14317	16432	18783	23117	25399	25312	10833
Dabigatran, n (%)	160 (1.2)	889 (6.5)	651 (4.7)	336 (2.4)	184 (1.3)	154 (0.9)	227 (1.2)	171 (0.7)	140 (0.6)	67 (0.3)	8 (0.1)
Rivaroxaban, n (%)	0 (0.0)	66 (0.5)	540 (3.9)	1010 (7.2)	1151 (8.0)	1070 (6.5)	1264 (6.7)	1770 (7.7)	1642 (6.5)	1430 (5.6)	619 (5.7)
Apixaban, n (%)	0 (0.0)	0 (0.0)	15 (0.1)	308 (2.2)	834 (5.8)	1606 (9.8)	2323 (12.4)	3664 (15.8)	4862 (19.1)	5647 (22.3)	2692 (24.8)
Warfarin, n (%)	2609 (20.2)	2169 (15.8)	2168 (15.7)	1782 (12.8)	1549 (10.8)	1520 (9.3)	1279 (6.8)	1243 (5.4)	782 (3.1)	608 (2.4)	232 (2.1)
None, n (%)	10142 (78.6)	10579 (77.2)	10438 (75.6)	10534 (75.4)	10599 (74.0)	12083 (73.5)	13690 (72.9)	16269 (70.4)	17974 (70.8)	17561 (69.4)	7282 (67.2)

Characteristics	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Asian, N	558	595	575	810	856	853	949	1103	1146	1146	459
Dabigatran, n (%)	6 (1.1)	32 (5.4)	18 (3.1)	31 (3.8)	17 (2.0)	12 (1.4)	16 (1.7)	12 (1.1)	5 (0.4)	3 (0.3)	0 (0.0)
Rivaroxaban, n (%)	0 (0.0)	0 (0.0)	25 (4.3)	57 (7.0)	60 (7.0)	62 (7.3)	65 (6.8)	102 (9.2)	95 (8.3)	56 (4.9)	20 (4.4)
Apixaban, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	14 (1.7)	45 (5.3)	74 (8.7)	131 (13.8)	163 (14.8)	236 (20.6)	252 (22.0)	120 (26.1)
Warfarin, n (%)	102 (18.3)	77 (12.9)	86 (15.0)	88 (10.9)	70 (8.2)	67 (7.9)	54 (5.7)	58 (5.3)	25 (2.2)	30 (2.6)	10 (2.2)
None, n (%)	450 (80.6)	486 (81.7)	446 (77.6)	620 (76.5)	664 (77.6)	638 (74.8)	683 (72.0)	768 (69.6)	785 (68.5)	805 (70.2)	309 (67.3)
Black, N	1986	2112	2148	2096	2075	2421	2960	4279	5101	4750	1908
Dabigatran, n (%)	20 (1.0)	128 (6.1)	90 (4.2)	43 (2.1)	24 (1.2)	13 (0.5)	23 (0.8)	14 (0.3)	17 (0.3)	10 (0.2)	0 (0.0)
Rivaroxaban, n (%)	0 (0.0)	7 (0.3)	84 (3.9)	108 (5.2)	127 (6.1)	130 (5.4)	169 (5.7)	299 (7.0)	308 (6.0)	223 (4.7)	91 (4.8)
Apixaban, n (%)	0 (0.0)	0 (0.0)	1 (0.0)	36 (1.7)	120 (5.8)	239 (9.9)	394 (13.3)	745 (17.4)	1075 (21.1)	1100 (23.2)	468 (24.5)
Warfarin, n (%)	361 (18.2)	352 (16.7)	340 (15.8)	263 (12.5)	174 (8.4)	193 (8.0)	186 (6.3)	181 (4.2)	87 (1.7)	63 (1.3)	28 (1.5)
None, n (%)	1605 (80.8)	1625 (76.9)	1633 (76.0)	1646 (78.5)	1630 (78.6)	1846 (76.2)	2188 (73.9)	3040 (71.0)	3615 (70.9)	3354 (70.6)	1321 (69.2)
Hispanic, N	2022	2063	2127	2430	2425	2858	3010	4323	4409	4406	1900
Dabigatran, n (%)	15 (0.7)	109 (5.3)	79 (3.7)	53 (2.2)	28 (1.2)	24 (0.8)	38 (1.3)	41 (0.9)	25 (0.6)	12 (0.3)	1 (0.1)
Rivaroxaban, n (%)	0 (0.0)	3 (0.1)	75 (3.5)	131 (5.4)	185 (7.6)	202 (7.1)	212 (7.0)	349 (8.1)	323 (7.3)	296 (6.7)	110 (5.8)
Apixaban, n (%)	0 (0.0)	0 (0.0)	3 (0.1)	51 (2.1)	135 (5.6)	273 (9.6)	357 (11.9)	706 (16.3)	944 (21.4)	1102 (25.0)	505 (26.6)
Warfarin, n (%)	408 (20.2)	366 (17.7)	365 (17.2)	363 (14.9)	301 (12.4)	304 (10.6)	215 (7.1)	232 (5.4)	118 (2.7)	76 (1.7)	32 (1.7)
None, n (%)	1599 (79.1)	1585 (76.8)	1605 (75.5)	1832 (75.4)	1776 (73.2)	2055 (71.9)	2188 (72.7)	2995 (69.3)	2999 (68.0)	2920 (66.3)	1252 (65.9)
White, N	21004	22133	21947	21968	21888	25628	28849	34322	38465	38366	16131
Dabigatran, n (%)	237 (1.1)	1,358 (6.1)	975 (4.4)	518 (2.4)	254 (1.2)	221 (0.9)	333 (1.2)	231 (0.7)	191 (0.5)	84 (0.2)	11 (0.1)
Rivaroxaban, n (%)	0 (0.0)	97 (0.4)	827 (3.8)	1555 (7.1)	1828 (8.4)	1691 (6.6)	1821 (6.3)	2488 (7.2)	2283 (5.9)	1953 (5.1)	852 (5.3)
Apixaban, n (%)	0 (0.0)	0 (0.0)	23 (0.1)	454 (2.1)	1308 (6.0)	2666 (10.4)	3800 (13.2)	5751 (16.8)	7594 (19.7)	8983 (23.4)	4141 (25.7)
Warfarin, n (%)	4034 (19.2)	3474 (15.7)	3420 (15.6)	2738 (12.5)	2345 (10.7)	2256 (8.8)	1984 (6.9)	1872 (5.5)	1160 (3.0)	875 (2.3)	337 (2.1)
None, n (%)	16733 (79.7)	17204 (77.7)	16702 (76.1)	16703 (76.0)	16153 (73.8)	18795 (73.3)	20911 (72.5)	23980 (69.9)	27237 (70.8)	26472 (69.0)	10793 (66.9)
Other, N	1212	1372	1339	1240	1511	1683	1891	1991	2115	2369	1205
Dabigatran, n (%)	13 (1.1)	74 (5.4)	60 (4.5)	29 (2.3)	26 (1.7)	11 (0.7)	19 (1.0)	15 (0.8)	13 (0.6)	7 (0.3)	3 (0.2)
Rivaroxaban, n (%)	0 (0.0)	11 (0.8)	55 (4.1)	81 (6.5)	100 (6.6)	91 (5.4)	110 (5.8)	129 (6.5)	102 (4.8)	120 (5.1)	62 (5.1)
Apixaban, n (%)	0 (0.0)	0 (0.0)	2 (0.1)	20 (1.6)	74 (4.9)	157 (9.3)	242 (12.8)	305 (15.3)	414 (19.6)	518 (21.9)	294 (24.4)
Warfarin, n (%)	209 (17.2)	194 (14.1)	191 (14.3)	125 (10.1)	214 (14.2)	164 (9.7)	140 (7.4)	89 (4.5)	59 (2.8)	54 (2.3)	29 (2.4)
None, n (%)	990 (81.7)	1093 (79.7)	1031 (77.0)	985 (79.4)	1097 (72.6)	1260 (74.9)	1380 (73.0)	1454 (73.0)	1528 (72.2)	1670 (70.5)	817 (67.8)
No Dementia, N	24000	25323	25356	25618	25840	30121	33532	40837	45183	45263	19089
Dabigatran, n (%)	279 (1.2)	1644 (6.5)	1176 (4.6)	645 (2.5)	344 (1.3)	268 (0.9)	412 (1.2)	295 (0.7)	242 (0.5)	107 (0.2)	13 (0.1)
Rivaroxaban, n (%)	0 (0.0)	112 (0.4)	1031 (4.1)	1843 (7.2)	2204 (8.5)	2062 (6.8)	2266 (6.8)	3161 (7.7)	2919 (6.5)	2504 (5.5)	1057 (5.5)
Apixaban, n (%)	0 (0.0)	0 (0.0)	25 (0.1)	551 (2.2)	1606 (6.2)	3249 (10.8)	4666 (13.9)	7138 (17.5)	9532 (21.1)	11040 (24.4)	5077 (26.6)
Warfarin, n (%)	4857 (20.2)	4221 (16.7)	4150 (16.4)	3359 (13.1)	2911 (11.3)	2822 (9.4)	2417 (7.2)	2291 (5.6)	1351 (3.0)	1037 (2.3)	418 (2.2)

Characteristics	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
None, n (%)	18864 (78.6)	19346 (76.4)	18974 (74.8)	19220 (75.0)	18775 (72.7)	21721 (72.1)	23771 (70.9)	27953 (68.5)	31140 (68.9)	30576 (67.6)	12527 (65.6)
Dementia, N	2782	2952	2780	2926	2915	3322	4127	5181	6053	5774	2514
Dabigatran, n (%)	12 (0.4)	57 (1.9)	46 (1.7)	29 (1.0)	5 (0.2)	13 (0.4)	17 (0.4)	18 (0.3)	9 (0.1)	9 (0.2)	2 (0.1)
Rivaroxaban, n (%)	0 (0.0)	6 (0.2)	35 (1.3)	89 (3.0)	96 (3.3)	114 (3.4)	111 (2.7)	206 (4.0)	192 (3.2)	144 (2.5)	78 (3.1)
Apixaban, n (%)	0 (0.0)	0 (0.0)	4 (0.1)	24 (0.8)	76 (2.6)	160 (4.8)	258 (6.3)	532 (10.3)	731 (12.1)	915 (15.8)	451 (17.9)
Warfarin, n (%)	257 (9.2)	242 (8.2)	252 (9.1)	218 (7.5)	193 (6.6)	162 (4.9)	162 (3.9)	141 (2.7)	98 (1.6)	61 (1.1)	18 (0.7)
None, n (%)	2513 (90.3)	2647 (89.7)	2443 (87.9)	2566 (87.7)	2545 (87.3)	2873 (86.5)	3579 (86.7)	4284 (82.7)	5024 (83.0)	4645 (80.4)	1965 (78.2)
Non-frail, N	22905	23987	23985	24247	24450	28410	31787	38625	42315	42418	18018
Dabigatran, n (%)	261 (1.1)	1592 (6.6)	1143 (4.8)	621 (2.6)	332 (1.4)	258 (0.9)	395 (1.2)	286 (0.7)	234 (0.6)	105 (0.2)	13 (0.1)
Rivaroxaban, n (%)	0 (0.0)	109 (0.5)	1001 (4.2)	1785 (7.4)	2122 (8.7)	1979 (7.0)	2179 (6.9)	3051 (7.9)	2774 (6.6)	2360 (5.6)	1005 (5.6)
Apixaban, n (%)	0 (0.0)	0 (0.0)	24 (0.1)	531 (2.2)	1541 (6.3)	3105 (10.9)	4400 (13.8)	6753 (17.5)	8900 (21.0)	10277 (24.2)	4755 (26.4)
Warfarin, n (%)	4633 (20.2)	3970 (16.6)	3875 (16.2)	3138 (12.9)	2725 (11.1)	2631 (9.3)	2272 (7.1)	2163 (5.6)	1273 (3.0)	969 (2.3)	402 (2.2)
None, n (%)	18011 (78.6)	18316 (76.4)	17942 (74.8)	18172 (74.9)	17730 (72.5)	20438 (71.9)	22541 (70.9)	26372 (68.3)	29135 (68.9)	28708 (67.7)	11845 (65.7)
Frail, N	3877	4288	4151	4297	4305	5033	5872	7393	8921	8619	3585
Dabigatran, n (%)	30 (0.8)	109 (2.5)	79 (1.9)	53 (1.2)	17 (0.4)	23 (0.5)	34 (0.6)	27 (0.4)	17 (0.2)	11 (0.1)	2 (0.1)
Rivaroxaban, n (%)	0 (0.0)	9 (0.2)	65 (1.6)	147 (3.4)	178 (4.1)	197 (3.9)	198 (3.4)	316 (4.3)	337 (3.8)	288 (3.3)	130 (3.6)
Apixaban, n (%)	0 (0.0)	0 (0.0)	5 (0.1)	44 (1.0)	141 (3.3)	304 (6.0)	524 (8.9)	917 (12.4)	1363 (15.3)	1678 (19.5)	773 (21.6)
Warfarin, n (%)	481 (12.4)	493 (11.5)	527 (12.7)	439 (10.2)	379 (8.8)	353 (7.0)	307 (5.2)	269 (3.6)	176 (2.0)	129 (1.5)	34 (0.9)
None, n (%)	3366 (86.8)	3677 (85.8)	3475 (83.7)	3614 (84.1)	3590 (83.4)	4156 (82.6)	4809 (81.9)	5865 (79.3)	7029 (78.8)	6513 (75.6)	2647 (73.8)
Stroke, N	2049	2078	2067	2160	2287	2755	3058	3808	4365	4173	1799
Dabigatran, n (%)	25 (1.2)	147 (7.1)	93 (4.5)	46 (2.1)	29 (1.3)	38 (1.4)	48 (1.6)	33 (0.9)	23 (0.5)	16 (0.4)	3 (0.2)
Rivaroxaban, n (%)	0 (0.0)	9 (0.4)	65 (3.1)	139 (6.4)	158 (6.9)	149 (5.4)	168 (5.5)	226 (5.9)	248 (5.7)	179 (4.3)	85 (4.7)
Apixaban, n (%)	0 (0.0)	0 (0.0)	3 (0.1)	38 (1.8)	164 (7.2)	327 (11.9)	470 (15.4)	711 (18.7)	1052 (24.1)	1097 (26.3)	490 (27.2)
Warfarin, n (%)	500 (24.4)	437 (21.0)	440 (21.3)	405 (18.8)	320 (14.0)	336 (12.2)	259 (8.5)	240 (6.3)	119 (2.7)	91 (2.2)	25 (1.4)
None, n (%)	1524 (74.4)	1485 (71.5)	1466 (70.9)	1532 (70.9)	1616 (70.7)	1905 (69.1)	2113 (69.1)	2598 (68.2)	2923 (67.0)	2790 (66.9)	1197 (66.5)
No stroke, N	24733	26197	26069	26384	26468	30688	34601	42210	46871	46864	19804
Dabigatran, n (%)	266 (1.1)	1554 (5.9)	1129 (4.3)	628 (2.4)	320 (1.2)	243 (0.8)	381 (1.1)	280 (0.7)	228 (0.5)	100 (0.2)	12 (0.1)
Rivaroxaban, n (%)	0 (0.0)	109 (0.4)	1001 (3.8)	1793 (6.8)	2142 (8.1)	2027 (6.6)	2209 (6.4)	3141 (7.4)	2863 (6.1)	2469 (5.3)	1050 (5.3)
Apixaban, n (%)	0 (0.0)	0 (0.0)	26 (0.1)	537 (2.0)	1518 (5.7)	3082 (10.0)	4454 (12.9)	6959 (16.5)	9211 (19.7)	10858 (23.2)	5038 (25.4)
Warfarin, n (%)	4614 (18.7)	4026 (15.4)	3962 (15.2)	3172 (12.0)	2784 (10.5)	2648 (8.6)	2320 (6.7)	2192 (5.2)	1330 (2.8)	1007 (2.1)	411 (2.1)
None, n (%)	19853 (80.3)	20508 (78.3)	19951 (76.5)	20254 (76.8)	19704 (74.4)	22689 (73.9)	25237 (72.9)	29639 (70.2)	33241 (70.9)	32431 (69.2)	13295 (67.1)
High											
CHA ₂ DS ₂ -VASc, N	22379	23475	23257	23580	23724	27510	31103	38258	43127	42934	18111
Dabigatran, n (%)	227 (1.0)	1356 (5.8)	989 (4.3)	550 (2.3)	280 (1.2)	220 (0.8)	336 (1.1)	261 (0.7)	201 (0.5)	98 (0.2)	11 (0.1)
Rivaroxaban, n (%)	0 (0.0)	89 (0.4)	839 (3.6)	1553 (6.6)	1837 (7.7)	1722 (6.3)	1852 (6.0)	2681 (7.0)	2466 (5.7)	2140 (5.0)	941 (5.2)

Characteristics	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Apixaban, n (%)	0 (0.0)	0 (0.0)	26 (0.1)	451 (1.9)	1361 (5.7)	2838 (10.3)	4090 (13.1)	6431 (16.8)	8708 (20.2)	10081 (23.5)	4662 (25.7)
Warfarin, n (%)	4311 (19.3)	3821 (16.3)	3798 (16.3)	3097 (13.1)	2580 (10.9)	2530 (9.2)	2150 (6.9)	2024 (5.3)	1186 (2.8)	916 (2.1)	331 (1.8)
None, n (%)	17841 (79.7)	18209 (77.6)	17605 (75.7)	17929 (76.0)	17666 (74.5)	20201 (73.4)	22675 (72.9)	26862 (70.2)	30568 (70.9)	29700 (69.2)	12169 (67.2)
Low											
CHA ₂ DS ₂ -VASc, N	4403	4800	4879	4964	5031	5933	6556	7760	8109	8103	3492
Dabigatran, n (%)	64 (1.5)	345 (7.2)	233 (4.8)	124 (2.5)	69 (1.4)	61 (1.0)	93 (1.4)	52 (0.7)	50 (0.6)	18 (0.2)	4 (0.1)
Rivaroxaban, n (%)	0 (0.0)	29 (0.6)	227 (4.7)	379 (7.6)	463 (9.2)	454 (7.7)	525 (8.0)	686 (8.8)	645 (8.0)	508 (6.3)	194 (5.6)
Apixaban, n (%)	0 (0.0)	0 (0.0)	3 (0.1)	124 (2.5)	321 (6.4)	571 (9.6)	834 (12.7)	1239 (16.0)	1555 (19.2)	1874 (23.1)	866 (24.8)
Warfarin, n (%)	803 (18.2)	642 (13.4)	604 (12.4)	480 (9.7)	524 (10.4)	454 (7.7)	429 (6.5)	408 (5.3)	263 (3.2)	182 (2.2)	105 (3.0)
None, n (%)	3536 (80.3)	3784 (78.8)	3812 (78.1)	3857 (77.7)	3654 (72.6)	4393 (74.0)	4675 (71.3)	5375 (69.3)	5596 (69.0)	5521 (68.1)	2323 (66.5)
High HAS-BLED ^a , N	14216	15186	15156	15153	15134	17751	20320	25648	29074	28985	12173
Dabigatran, n (%)	149 (1.0)	940 (6.2)	638 (4.2)	356 (2.3)	158 (1.0)	154 (0.9)	244 (1.2)	175 (0.7)	146 (0.5)	65 (0.2)	9 (0.1)
Rivaroxaban, n (%)	0 (0.0)	69 (0.5)	577 (3.8)	1033 (6.8)	1204 (8.0)	1128 (6.4)	1281 (6.3)	1823 (7.1)	1716 (5.9)	1505 (5.2)	605 (5.0)
Apixaban, n (%)	0 (0.0)	0 (0.0)	24 (0.2)	276 (1.8)	882 (5.8)	1840 (10.4)	2729 (13.4)	4369 (17.0)	6162 (21.2)	7138 (24.6)	3240 (26.6)
Warfarin, n (%)	2842 (20.0)	2484 (16.4)	2467 (16.3)	2014 (13.3)	1580 (10.4)	1700 (9.6)	1434 (7.1)	1307 (5.1)	827 (2.8)	598 (2.1)	208 (1.7)
None, n (%)	11225 (79.0)	11693 (77.0)	11450 (75.5)	11474 (75.7)	11310 (74.7)	12929 (72.8)	14632 (72.0)	17975 (70.1)	20225 (69.6)	19679 (67.9)	8113 (66.6)
Low HAS-BLED ^a , N	12566	13089	12980	13,391	13621	15692	17339	20370	22162	22052	9430
Dabigatran, n (%)	142 (1.1)	761 (5.8)	584 (4.5)	318 (2.4)	191 (1.4)	127 (0.8)	185 (1.1)	138 (0.7)	105 (0.5)	51 (0.2)	6 (0.1)
Rivaroxaban, n (%)	0 (0.0)	49 (0.4)	489 (3.8)	899 (6.7)	1096 (8.0)	1048 (6.7)	1096 (6.3)	1544 (7.6)	1395 (6.3)	1143 (5.2)	530 (5.6)
Apixaban, n (%)	0 (0.0)	0 (0.0)	5 (0.0)	299 (2.2)	800 (5.9)	1569 (10.0)	2195 (12.7)	3301 (16.2)	4101 (18.5)	4817 (21.8)	2288 (24.3)
Warfarin, n (%)	2272 (18.1)	1979 (15.1)	1935 (14.9)	1563 (11.7)	1524 (11.2)	1284 (8.2)	1145 (6.6)	1125 (5.5)	622 (2.8)	500 (2.3)	228 (2.4)
None, n (%)	10152 (80.8)	10300 (78.7)	9967 (76.8)	10312 (77.0)	10010 (73.5)	11665 (74.3)	12718 (73.3)	14262 (70.0)	15939 (71.9)	15542 (70.5)	6379 (67.6)
Anemia, N	6614	7165	7323	7517	7437	8558	9735	12078	14384	14144	5970
Dabigatran, n (%)	56 (0.8)	304 (4.2)	225 (3.1)	136 (1.8)	55 (0.7)	57 (0.7)	74 (0.8)	69 (0.6)	61 (0.4)	22 (0.2)	2 (0.0)
Rivaroxaban, n (%)	0 (0.0)	15 (0.2)	205 (2.8)	355 (4.7)	446 (6.0)	414 (4.8)	433 (4.4)	681 (5.6)	666 (4.6)	546 (3.9)	221 (3.7)
Apixaban, n (%)	0 (0.0)	0 (0.0)	11 (0.2)	92 (1.2)	317 (4.3)	682 (8.0)	976 (10.0)	1707 (14.1)	2538 (17.6)	3005 (21.2)	1427 (23.9)
Warfarin, n (%)	1076 (16.3)	1043 (14.6)	1038 (14.2)	906 (12.1)	723 (9.7)	727 (8.5)	650 (6.7)	586 (4.9)	402 (2.8)	278 (2.0)	103 (1.7)
None, %	5482 (82.9)	5803 (81.0)	5844 (79.8)	6028 (80.2)	5896 (79.3)	6678 (78.0)	7602 (78.1)	9036 (74.8)	10718 (74.5)	10293 (72.8)	4218 (70.7)
No Anemia, N	20168	21110	20813	21027	21318	24885	27924	33940	36852	36893	15633
Dabigatran, n (%)	235 (1.2)	1397 (6.6)	997 (4.8)	538 (2.6)	294 (1.4)	224 (0.9)	355 (1.3)	244 (0.7)	190 (0.5)	94 (0.3)	13 (0.1)
Rivaroxaban, n (%)	0 (0.0)	103 (0.5)	861 (4.1)	1577 (7.5)	1854 (8.7)	1762 (7.1)	1944 (7.0)	2686 (7.9)	2445 (6.6)	2102 (5.7)	914 (5.8)
Apixaban, n (%)	0 (0.0)	0 (0.0)	18 (0.1)	483 (2.3)	1365 (6.4)	2727 (11.0)	3948 (14.1)	5963 (17.6)	7725 (21.0)	8950 (24.3)	4101 (26.2)
Warfarin, n (%)	4038 (20.0)	3420 (16.2)	3364 (16.2)	2671 (12.7)	2381 (11.2)	2257 (9.1)	1929 (6.9)	1846 (5.4)	1047 (2.8)	820 (2.2)	333 (2.1)
None, n (%)	15895 (78.8)	16190 (76.7)	15573 (74.8)	15758 (74.9)	15424 (72.4)	17916 (72.0)	19748 (70.7)	23201 (68.4)	25446 (69.0)	24928 (67.6)	10274 (65.7)

Characteristics	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Chronic Kidney Disease, N	5284	6303	6608	,945	7275	9105	11710	15429	17829	18366	7905
Dabigatran, n (%)	44 (0.8)	253 (4.0)	193 (2.9)	118 (1.7)	58 (0.8)	64 (0.7)	105 (0.9)	109 (0.7)	79 (0.4)	41 (0.2)	4 (0.1)
Rivaroxaban, n (%)	0 (0.0)	16 (0.3)	190 (2.9)	372 (5.4)	441 (6.1)	465 (5.1)	591 (5.0)	946 (6.1)	924 (5.2)	884 (4.8)	396 (5.0)
Apixaban, n (%)	0 (0.0)	0 (0.0)	4 (0.1)	101 (1.5)	389 (5.3)	869 (9.5)	1514 (12.9)	2599 (16.8)	3649 (20.5)	4472 (24.3)	2051 (25.9)
Warfarin, n (%)	964 (18.2)	1071 (17.0)	1130 (17.1)	1016 (14.6)	886 (12.2)	953 (10.5)	916 (7.8)	916 (5.9)	543 (3.0)	421 (2.3)	134 (1.7)
None, n (%)	4276 (80.9)	4963 (78.7)	5091 (77.0)	5338 (76.9)	5501 (75.6)	6754 (74.2)	8584 (73.3)	10860 (70.4)	12634 (70.9)	12548 (68.3)	5322 (67.3)
No Chronic Kidney Disease, N	21498	21,972	21528	21599	21480	24338	25949	30589	33407	32671	13698
Dabigatran, n (%)	247 (1.1)	1448 (6.6)	1029 (4.8)	556 (2.6)	291 (1.4)	217 (0.9)	324 (1.2)	204 (0.7)	172 (0.5)	75 (0.2)	11 (0.1)
Rivaroxaban, n (%)	0 (0.0)	102 (0.5)	876 (4.1)	1560 (7.2)	1859 (8.7)	1711 (7.0)	1786 (6.9)	2421 (7.9)	2187 (6.5)	1764 (5.4)	739 (5.4)
Apixaban, n (%)	0 (0.0)	0 (0.0)	25 (0.1)	474 (2.2)	1293 (6.0)	2540 (10.4)	3410 (13.1)	5071 (16.6)	6614 (19.8)	7483 (22.9)	3477 (25.4)
Warfarin, n (%)	4150 (19.3)	3392 (15.4)	3272 (15.2)	2561 (11.9)	2218 (10.3)	2031 (8.3)	1663 (6.4)	1516 (5.0)	906 (2.7)	677 (2.1)	302 (2.2)
None, n (%)	17101 (79.5)	17030 (77.5)	16326 (75.8)	16448 (76.2)	15819 (73.6)	17840 (73.2)	18766 (72.3)	21377 (69.9)	23530 (70.4)	22673 (69.4)	9170 (66.9)

Abbreviations: CHA₂DS₂-VASc score assigns 1 point for congestive heart failure, 1 point for hypertension, 2 points for age 75 years or older, 1 point for age 65 to 74 years, 1 point for diabetes mellitus, 2 points for history of stroke or transient ischemic attack or systemic thromboembolism, 1 point for vascular disease including myocardial infarction or peripheral arterial disease, and 1 point for female sex; HAS-BLED score assigns 1 point each for hypertension, renal disease, liver disease, prior stroke, prior history of bleeding, age greater than 65, use of aspirin and other antiplatelets, and alcohol use disorder

^aExcluded labile international normalized ratio component

eTable 2. OAC Mean Proportion of Days Covered and Nonadherence (Proportion of Days Covered < 80%) in OAC-Initiator Incident Atrial Fibrillation Cohort, 2010-2020

Characteristics	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
All, N	4389	6263	6665	6743	7096	8703	10175	12876	15509	15874	8798
Median PDC [IQR]	77.6 [41.0, 96.4]	79.2 [41.0, 96.7]	82.0 [42.9, 97.3]	82.2 [49.2, 97.8]	82.0 [43.7, 96.7]	86.1 [57.1, 98.1]	86.9 [57.4, 97.8]	88.3 [57.4, 98.1]	87.2 [53.9, 98.1]	89.3 [57.4, 98.4]	90.2 [57.4, 98.6]
Non-adherent, n (%)	2290 (52.2)	3161 (50.5)	3169 (47.5)	3104 (46.0)	2175 (45.2)	3664 (42.1)	4221 (41.5)	5068 (39.4)	6442 (41.5)	6161 (38.8)	3434 (39.0)
Age 65-79 years, N	3221	4102	4078	4015	4377	5365	6370	8260	10092	10406	5746
Median PDC [IQR]	78.4 [41.9, 96.4]	78.7 [41.0, 96.4]	82.0 [41.0, 96.7]	82.0 [49.2, 97.5]	81.4 [41.0, 96.4]	85.8 [54.4, 98.1]	86.6 [55.2, 97.8]	88.0 [57.4, 97.8]	86.9 [52.2, 98.1]	89.3 [57.4, 98.4]	90.2 [57.4, 98.6]
Non-adherent, n (%)	1651 (51.3)	2090 (51.0)	1962 (48.1)	1875 (46.7)	2136 (48.8)	2292 (42.7)	2657 (41.7)	3284 (39.8)	4222 (41.8)	4116 (39.6)	2254 (39.2)
Age ≥80 years, N	1168	2161	2587	2728	2719	3338	3805	4616	5417	5468	3052
Median PDC [IQR]	73.8 [41.0, 96.2]	80.6 [42.7, 97.5]	82.0 [47.5, 98.4]	82.8 [49.2, 98.1]	82.2 [49.2, 97.3]	86.3 [57.4, 98.4]	86.9 [57.4, 97.5]	88.8 [59.4, 98.1]	87.4 [57.4, 98.4]	89.6 [58.1, 98.4]	89.9 [57.4, 98.8]
Non-adherent, n (%)	639 (54.7)	1071 (49.6)	1207 (46.7)	1229 (45.1)	1257 (46.2)	1372 (41.1)	1564 (41.1)	1784 (38.6)	2220 (41.0)	2045 (37.4)	1180 (38.7)
Women, N	2154	3142	3323	3332	3523	4372	5196	6499	7880	8070	4363
Median PDC [IQR]	78.1 [44.5, 97.0]	81.3 [45.3, 97.5]	82.0 [49.2, 97.8]	84.2 [49.2, 98.4]	82.5 [49.2, 97.3]	86.7 [57.4, 98.4]	87.3 [57.7, 97.8]	89.6 [63.4, 98.4]	88.5 [57.4, 98.4]	90.2 [62.3, 98.6]	91.0 [61.3, 99.2]
Non-adherent, n (%)	1106 (51.3)	1534 (48.8)	1552 (46.7)	1467 (44.0)	1619 (46.0)	1800 (41.2)	2084 (40.1)	2418 (37.2)	3095 (39.3)	2926 (36.3)	1580 (36.2)
Men, N	2235	3121	3342	3411	3573	4331	4979	6377	7629	7804	4435
Median PDC [IQR]	76.5 [41.0, 95.6]	77.6 [39.2, 95.9]	82.0 [41.0, 97.0]	82.0 [47.5, 97.0]	80.3 [41.0, 96.2]	85.2 [50.8, 97.8]	86.1 [51.9, 97.5]	86.6 [55.1, 97.8]	85.0 [49.2, 97.8]	87.4 [52.2, 98.4]	87.7 [51.9, 98.4]
Non-adherent, n (%)	1184 (53.0)	1627 (52.1)	1617 (48.4)	1637 (48.0)	1774 (49.7)	1864 (43.0)	2137 (42.9)	2650 (41.6)	3347 (43.9)	3235 (41.5)	1854 (41.8)
Asian, N	3475	4912	5207	5269	5586	6640	7827	9792	11481	11921	6580
Median PDC [IQR]	77.6 [42.3, 96.4]	79.2 [41.0, 97.0]	82.0 [42.9, 97.3]	83.1 [49.2, 97.8]	82.0 [48.6, 97.0]	86.9 [57.4, 98.4]	88.0 [57.4, 98.1]	89.3 [59.6, 98.3]	88.8 [57.4, 98.4]	90.2 [58.5, 98.6]	90.2 [57.7, 98.9]
Non-adherent, n (%)	1816 (52.3)	2478 (50.4)	2474 (47.5)	2371 (45.0)	2582 (46.2)	2734 (41.2)	3122 (39.9)	3722 (38.0)	4520 (39.4)	4401 (36.9)	2471 (37.6)
Black, N	310	475	505	471	438	528	753	1074	1558	1424	759
Median PDC [IQR]	73.8 [41.0, 95.2]	77.9 [32.8, 97.5]	82.0 [49.2, 96.6]	79.8 [41.7, 95.4]	75.3 [39.0, 94.9]	82.9 [49.2, 97.5]	84.2 [49.2, 96.4]	85.1 [52.4, 97.0]	82.0 [46.6, 96.2]	83.6 [53.6, 97.0]	84.7 [49.2, 98.1]
Non-adherent, n (%)	174 (56.1)	250 (52.6)	233 (46.1)	236 (50.1)	237 (54.1)	242 (45.8)	336 (44.6)	467 (43.5)	734 (47.1)	622 (43.7)	340 (44.8)
Hispanic, N	343	485	520	581	626	773	820	1190	1494	1496	812
Median PDC [IQR]	80.1 [41.0, 97.3]	79.8 [46.6, 94.5]	82.0 [42.0, 98.4]	81.1 [49.2, 97.8]	73.8 [41.0, 95.1]	81.1 [45.6, 95.4]	76.8 [41.0, 95.3]	82.8 [49.2, 96.4]	80.3 [41.9, 96.2]	82.0 [49.2, 96.7]	83.4 [49.2, 97.8]
Non-adherent, n (%)	171 (49.9)	243 (50.1)	249 (47.9)	288 (49.6)	343 (54.8)	377 (48.8)	433 (52.8)	535 (45.0)	744 (49.8)	729 (48.7)	365 (45.0)
White, N	91	114	125	172	191	209	260	325	365	355	184
Median PDC [IQR]	86.6 [49.2, 98.9]	83.2 [34.4, 97.1]	82.0 [41.0, 97.5]	76.2 [40.9, 98.4]	82.0 [41.0, 97.0]	89.1 [58.9, 98.0]	86.9 [53.3, 98.3]	87.2 [57.4, 98.4]	82.0 [49.2, 98.4]	89.1 [49.2, 98.6]	88.1 [52.4, 98.4]


Characteristics	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Non-adherent, n (%)	38 (41.8)	52 (45.6)	60 (48.0)	88 (51.2)	94 (49.2)	86 (41.1)	105 (40.4)	135 (41.5)	175 (47.9)	138 (38.9)	75 (40.8)
Other, N	170	277	308	250	255	553	515	495	611	678	463
Median PDC [IQR]	72.5	80.6	80.3	82.2	73.8	85.5	86.1	87.4	83.6	88.5	90.4
Non-adherent, n (%)	[35.5, 94.9]	[35.1, 95.6]	[33.1, 97.7]	[49.2, 97.8]	[32.8, 96.2]	[57.8, 97.5]	[49.2, 97.5]	[60.7, 98.1]	[51.1, 98.1]	[57.4, 98.4]	[57.4, 98.4]
No Dementia, N	91 (53.5)	138 (49.8)	153 (49.7)	121 (48.4)	137 (53.7)	225 (40.7)	225 (43.7)	209 (42.2)	269 (44.0)	271 (40.0)	183 (39.5)
Median PDC [IQR]	4112	5841	6196	6268	6613	8101	9365	11763	14044	14385	7888
Non-adherent, n (%)	77.7	79.5	82.0	82.2	82.0	86.3	87.2	88.5	87.4	89.6	90.2
Dementia, N	2138 (52.0)	2936 (50.3)	2949 (47.6)	2890 (46.1)	3168 (47.9)	3388 (41.8)	386 (47.7)	4577 (38.9)	5773 (41.1)	5537 (38.5)	3032 (38.4)
Median PDC [IQR]	277	422	469	475	483	602	810	1113	1465	1489	910
Non-adherent, n (%)	73.2	74.5	82.0	82.5	83.3	83.2	82.0	85.0	83.9	86.3	86.1
Non-frail, N	152 (54.9)	225 (53.3)	220 (46.9)	214 (45.1)	225 (46.6)	276 (45.8)	3835 (41.0)	491 (44.1)	669 (45.7)	624 (41.9)	402 (44.2)
Median PDC [IQR]	3696	5161	5545	5508	5895	7206	8466	10667	12466	12866	6930
Non-adherent, n (%)	77.9	79.8	82.0	82.5	82.0	86.9	87.7	89.1	88.3	90.2	90.2
Frail, N	1916 (51.8)	2586 (50.1)	2600 (46.9)	2528 (45.9)	2810 (47.7)	2961 (41.1)	3408 (40.3)	4061 (38.1)	5004 (40.1)	4815 (37.4)	2609 (37.6)
Median PDC [IQR]	693	1102	1120	1235	1201	1497	1709	2209	3043	3008	1868
Non-adherent, n (%)	75.1	77.5	79.0	82.0	82.0	82.0	82.0	83.1	82.0	83.9	85.6
Stroke, N	374 (54.0)	575 (52.2)	569 (50.8)	576 (46.6)	583 (48.5)	703 (47.0)	813 (47.6)	1007 (45.6)	1438 (47.3)	1346 (44.7)	825 (44.2)
Median PDC [IQR]	657	918	922	990	966	1142	1352	1559	2054	1960	1146
Non-adherent, n (%)	82.2	84.4	88.0	88.1	88.7	88.3	89.3	90.4	89.1	89.9	92.6
No stroke, N	310 (47.2)	391 (42.6)	376 (40.8)	400 (40.4)	385 (39.9)	439 (38.4)	511 (37.8)	545 (35.0)	808 (39.3)	724 (36.9)	390 (34.0)
Median PDC [IQR]	3732	5345	5743	5753	6130	7561	8823	11317	13455	13914	7652
Non-adherent, n (%)	76.2	77.9	81.4	82.0	80.9	85.8	86.3	87.7	86.6	89.3	89.3
High CHA ₂ DS ₂ -VASc, N	1980 (53.1)	2770 (51.8)	2793 (48.6)	2704 (47.0)	3008 (49.1)	3225 (42.7)	3710 (42.0)	4523 (40.0)	5634 (41.9)	5437 (39.1)	3044 (39.8)
Median PDC [IQR]	3917	5598	5952	6029	6257	7573	8859	11203	13644	13950	7745
Non-adherent, n (%)	77.6	79.5	82.0	82.1	82.0	85.5	86.3	87.7	86.1	88.8	89.3
Low CHA ₂ DS ₂ -VASc, N	2045 (52.2)	2816 (50.3)	2797 (47.0)	2781 (46.1)	2978 (47.6)	3227 (42.6)	3711 (41.9)	4469 (39.9)	5793 (42.5)	5490 (39.4)	3073 (39.7)
Median PDC [IQR]	472	665	713	714	839	1130	1316	1673	1865	1924	1053
Non-adherent, n (%)	76.8	78.7	77.9	82.8	80.3	89.3	90.2	90.4	91.3	91.8	92.6
Non-adherent, n (%)	[35.1, 97.2]	[32.8, 96.2]	[32.8, 95.6]	[49.0, 97.3]	[41.0, 96.7]	[57.4, 98.4]	[57.4, 98.4]	[65.6, 98.4]	[62.0, 98.4]	[65.6, 98.6]	[63.9, 99.5]
Non-adherent, n (%)	245 (51.9)	345 (51.9)	372 (52.2)	323 (45.2)	415 (49.5)	437 (38.7)	510 (38.8)	599 (35.8)	649 (34.8)	671 (34.9)	361 (34.3)

Characteristics	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
High HAS-BLED ^a , N	2795	4064	4247	4303	4415	5269	6409	8120	10214	10422	5845
Median PDC [IQR]	77.6	78.7	82.0	82.0	81.7	84.7	85.5	87.2	85.2	88.0	89.6
Non-adherent, n (%)	[41.0, 96.2]	[41.0, 97.0]	[41.0, 97.5]	[47.8, 97.5]	[41.0, 96.7]	[51.6, 97.8]	[54.4, 97.5]	[56.6, 97.8]	[49.2, 97.8]	[55.7, 98.4]	[57.4, 98.5]
Low HAS-BLED ^a , N	1594	2199	2418	2440	2681	3434	3766	4756	5295	5452	2953
Median PDC [IQR]	77.6	80.3	82.0	83.7	82.0	88.0	88.8	89.9	90.2	90.7	90.2
Non-adherent, n (%)	[45.1, 96.8]	[46.2, 96.4]	[49.2, 97.0]	[49.2, 98.1]	[49.2, 97.0]	[58.4, 98.4]	[58.7, 98.1]	[65.6, 98.4]	[59.6, 98.4]	[64.5, 98.6]	[57.4, 98.9]
Anemia, N	1107	1746	1793	1907	1858	2249	2631	3418	4498	4565	2682
Median PDC [IQR]	69.6	72.7	76.5	79.5	78.1	82.0	82.2	82.8	82.0	84.7	86.9
Non-adherent, n (%)	[31.1 93.2]	[29.7 95.9]	[32.8 96.3]	[36.9 97.0]	[35.5 96.2]	[47.6 97.5]	[49.2 96.7]	[48.6 97.3]	[44.0 96.9]	[49.2 97.8]	[49.2 98.4]
No Anemia, N	649 (58.6)	964 (55.2)	943 (52.6)	960 (50.3)	952 (51.2)	1051 (46.7)	1208 (45.9)	1557 (45.6)	2163 (48.1)	2032 (44.5)	1152 (43.0)
Median PDC [IQR]	79.9	81.4	82.2	83.3	82.0	87.2	88.3	89.6	89.1	90.2	90.4
Non-adherent, n (%)	[48.6 97.0]	[49.2 97.0]	[49.2 97.5]	[50.0 97.8]	[49.2 96.7]	[57.4 98.4]	[57.4 98.1]	[63.9 98.4]	[57.4 98.4]	[62.0 98.6]	[58.5 98.9]
Chronic Kidney Disease, N	1013	1609	1817	1928	2032	2745	3658	4786	6245	6633	3804
Median PDC [IQR]	74.3	77.3	79.8	81.7	81.1	85.0	83.1	85.5	83.6	86.1	86.6
Non-adherent, n (%)	[41.0 95.8]	[36.2 97.0]	[41.0 97.3]	[41.0 97.5]	[41.0 97.3]	[50.0 97.8]	[50.1 97.0]	[54.4 97.5]	[49.2 97.4]	[52.3 98.1]	[51.5 98.4]
No Chronic Kidney Disease, N	547 (54.0)	839 (52.1)	910 (50.1)	929 (48.2)	1002 (49.3)	1198 (43.6)	1664 (45.5)	2040 (42.6)	2827 (45.3)	2807 (42.3)	1604 (42.2)
Median PDC [IQR]	3376	4654	4848	4815	5064	5958	6517	8090	9264	9241	4994
Non-adherent, n (%)	77.9	80.1	82.0	83.1	82.0	86.3	88.5	89.9	89.1	90.7	91.0
Median PDC [IQR]	[42.9 96.7]	[41.0 96.7]	[45.9 97.3]	[49.2 97.8]	[45.1 96.4]	[57.4 98.4]	[57.4 98.1]	[62.3 98.4]	[57.4 98.4]	[60.5 98.6]	[59.6 99.2]
Non-adherent, n (%)	1743 (51.6)	2322 (49.9)	2259 (46.6)	2175 (45.2)	2391 (47.2)	2466 (41.4)	2557 (39.2)	3028 (37.4)	3615 (39.0)	3354 (36.3)	1830 (36.6)

Abbreviations: CHA₂DS₂-VASc score assigns 1 point for congestive heart failure, 1 point for hypertension, 2 points for age 75 years or older, 1 point for age 65 to 74 years, 1 point for diabetes mellitus, 2 points for history of stroke or transient ischemic attack or systemic thromboembolism, 1 point for vascular disease including myocardial infarction or peripheral arterial disease, and 1 point for female sex; HAS-BLED score assigns 1 point each for hypertension, renal disease, liver disease, prior stroke, prior history of bleeding, age greater than 65, use of aspirin and other antiplatelets, and alcohol use disorder; PDC, proportion of days covered

^aExcluded labile international normalized ratio component

eFigure. OAC Initiation and DOAC Uptake by Race and Additional Clinical Subgroups Over 2010-2020



eFigure. The stacked area plots depict the proportion of OAC use and DOAC update in the OAC-eligible incident AF cohort stratified by race, HAS-BLED score, and stroke. There was an increase in patients of Asian (OR for OAC initiation per year: 1.09, 95% CI 1.07-1.10, $P < 0.001$), Black (OR for OAC initiation per year: 1.06, 95% CI 1.05-1.07, $P < 0.001$), and Other (OR for OAC initiation per year: 1.04, 95% CI 1.05-1.07, $P < 0.001$), White (OR for OAC initiation per year: 1.06, 95% CI 1.06-1.07, $P < 0.001$) race, and Hispanic ethnicity (OR for OAC initiation per year, 1.07, 95% CI 1.07-1.08, $P < 0.001$). There was an increase in OAC initiation in patients with lower (OR for OAC initiation per year, 1.06, 95% CI 1.06-1.07, $P < 0.001$) and higher (OR for OAC initiation per year, 1.07, 95% CI 1.06-1.07, $P < 0.001$) HAS-BLED and with (OR for OAC initiation per year, 1.03, 95% CI 1.02-1.04, $P < 0.001$) and without prior stroke (OR for OAC initiation per year, 1.07, 95% CI 1.06-1.07, $P < 0.001$).